DISPERSIBLE TABLETS — PROSPECTS FOR THE DEVELOPMENT OF A NEW DOSAGE FORM: CASE STUDY OF NYSTATIN DISPERSIBLE TABLET FORMULATION

Annotasiya

Dispersible tablets are one of the most promising solid dosage forms, offering ease of use, especially for patients with swallowing difficulties such as children, the elderly, and patients with dysphagia

Manba turi: Jurnallar
Yildan beri qamrab olingan yillar 2021
inLibrary
Google Scholar
f
97
0

Кўчирилди

Кўчирилганлиги хақида маълумот йук.
Ulashish
Almatov , A., Bulusov , J., & Odilova , D. (2025). DISPERSIBLE TABLETS — PROSPECTS FOR THE DEVELOPMENT OF A NEW DOSAGE FORM: CASE STUDY OF NYSTATIN DISPERSIBLE TABLET FORMULATION . Yevrosiyo Ilmiy Tadqiqotlar Jurnali, 5(10(MPHAPP), 97. Retrieved from https://inlibrary.uz/index.php/ejar/article/view/138234
0
Iqtibos
Crossref
Сrossref
Scopus
Scopus

Annotasiya

Dispersible tablets are one of the most promising solid dosage forms, offering ease of use, especially for patients with swallowing difficulties such as children, the elderly, and patients with dysphagia


background image

97

Volume 5, Issue 10: Special Issue
(EJAR)

ISSN: 2181-2020

MPHAPP

THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE

MODERN PHARMACEUTICS: ACTUAL

PROBLEMS AND PROSPECTS

TASHKENT, OCTOBER 17, 2025

in-academy.uz

DISPERSIBLE TABLETS

PROSPECTS FOR THE DEVELOPMENT OF A NEW

DOSAGE FORM: CASE STUDY OF NYSTATIN DISPERSIBLE TABLET

FORMULATION

Almatov A.T.

1

Bulusov J.K.

2

Odilova D.M.

3

State «Center for Good Practices», Tashkent Region, Republic of

Uzbekistan

e-mail: Atalmatov@list.ru

https://doi.org/10.5281/zenodo.17322238

Relevance:

Dispersible tablets are one of the most promising solid dosage forms, offering ease

of use, especially for patients with swallowing difficulties such as children, the elderly, and patients
with dysphagia. The ability to obtain a suspension from a tablet immediately before administration
makes this form attractive for expanding the range of oral drugs, including antifungal agents like
nystatin.

Objective of the Study:

To develop and optimize the formulation of nystatin dispersible tablets

suitable for use as a suspension in patients who have difficulty taking solid oral forms.

Materials and Methods:

Active substance:

Nystatin

Initial formulations:

10 variants with

different types of disintegrants and fillers, as well as other excipients, including flavoring agents and
sweeteners.

Excipients used:

Croscarmellose sodium, sodium starch glycolate, povidone, sorbitol,

mannitol, microcrystalline cellulose (MCC), starch, lactose, xanthan gum, and their combinations.

Parameters evaluated:

Appearance, weight, hardness, disintegration time.

Equipment:

ERWEKA ZT 320 Tablet and Capsule Disintegration Tester; ERWEKA TAR 220

Friability Tester; PTK PR-LM Tablet Press FRITSCH laboratory sieves with sizes: 0.4 mm; 0.6 mm;
0.8 mm

Results:

Initially, the impact of various disintegrants was studied; however, achieving the

regulatory disintegration time (within 3 minutes) was not successful. After shifting focus to the
selection and combination of fillers, satisfactory disintegration results were still not achieved. None
of the tested formulations provided stable disintegration within the required time frame. Variants with
croscarmellose sodium and sodium starch glycolate demonstrated acceptable disintegration times but
produced tablets that were too fragile. The addition of povidone improved mechanical strength but
negatively affected dispersibility. Formulations containing starch and sodium carboxymethyl starch
showed uneven disintegration and a tendency to form gels. Variants with microcrystalline cellulose
had satisfactory mechanical properties but poor dispersibility. In all cases, high sensitivity of the
composition to humidity was observed, which complicated the tableting process.

Conclusion:

The development of an effective dispersible dosage form of nystatin proved to be

more challenging than initially anticipated. The study showed that the choice of fillers and their
combinations significantly influences tablet disintegration, and none of the tested formulations met
the required standards. Further research is needed to identify suitable functional excipients, possibly
involving modern super-disintegrants and particle surface modification technologies.